Robert Markewitz

TL;DR: In this paper, the efficacy and safety of anti-SARS-CoV-2 mRNA vaccines in a cohort of immunosuppressed patients as compared with healthy controls were presented for the first time.

TL;DR: The study demonstrates broad cellular effects of SARS-CoV-2 infection beyond classical immune cells and may serve as an entry point to develop biomarkers and targeted treatments of patients with COVID-19.

TL;DR: These findings identify low avidity CD4+T cell responses as a hallmark of severe COVID-19, and argue against a protective role for CCCoV reactive T cells in SARS-CoV-2 infection.

TL;DR: Subacute disease onset and early inflammatory CSF changes support the primary role of autoimmune mechanisms at at initial stages of anti-IgLON5 disease and early immunotherapy, prior to advanced neurodegeneration, is associated with a better long-term clinical outcome.

TL;DR: The data suggest that a low avidity pre-existing T cell memory negatively impacts on the T cell response quality against neoantigens such as SARS-CoV-2, which may predispose to develop inappropriate immune reactions especially in the elderly.